<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Chromatogr B Analyt Technol Biomed Life Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Chromatogr. B Analyt. Technol. Biomed. Life Sci</journal-id><journal-id journal-id-type="pmc-domain-id">445</journal-id><journal-id journal-id-type="pmc-domain">elsevierwt</journal-id><journal-title-group><journal-title>Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences</journal-title></journal-title-group><issn pub-type="ppub">1570-0232</issn><issn pub-type="epub">1873-376X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier Sponsored Documents</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6522057</article-id><article-id pub-id-type="pmcid-ver">PMC6522057.1</article-id><article-id pub-id-type="pmcaid">6522057</article-id><article-id pub-id-type="pmcaiid">6522057</article-id><article-id pub-id-type="pmid">31005772</article-id><article-id pub-id-type="doi">10.1016/j.jchromb.2019.04.026</article-id><article-id pub-id-type="publisher-id">S1570-0232(18)31719-7</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Analysis of PK11195 concentrations in rodent whole blood and tissue samples by rapid and reproducible chromatographic method to support target-occupancy PET studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Stadulyt&#279;</surname><given-names initials="A">Agn&#279;</given-names></name><email>A.Stadulyte@sms.ed.ac.uk</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alcaide-Corral</surname><given-names initials="CJ">Carlos Jos&#233;</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walton</surname><given-names initials="T">Tashfeen</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lucatelli</surname><given-names initials="C">Christophe</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tavares</surname><given-names initials="AAS">Adriana Alexandre S.</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib></contrib-group><aff id="af0005"><label>a</label>University/BHF Centre for Cardiovascular Science, University of Edinburgh, UK</aff><aff id="af0010"><label>b</label>Edinburgh Preclinical Imaging (EPI), University of Edinburgh, UK</aff><aff id="af0015"><label>c</label>Edinburgh Imaging, Queen's Medical Research Institute, University of Edinburgh, UK</aff><author-notes><corresp id="cr0005"><label>&#8270;</label>Corresponding author at: 47 Little France Crescent, Centre of Cardiovascular Sciences, Queen's Medical Research Institute, EH16 4TJ Edinburgh, United Kingdom. <email>A.Stadulyte@sms.ed.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>6</month><year>2019</year></pub-date><volume>1118-1119</volume><issue-id pub-id-type="pmc-issue-id">334805</issue-id><fpage>33</fpage><lpage>39</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2018</year></date><date date-type="rev-recd"><day>5</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>06</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>15</day><month>06</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-11-14 12:10:16.227"><day>14</day><month>11</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; 2019 The Authors</copyright-statement><copyright-year>2019</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab0005"><p>In Positron Emission Tomography (PET) research, it is important to assess not only pharmacokinetics of a radiotracer <italic toggle="yes">in vivo</italic>, but also of the drugs used in blocking/displacement PET studies. Typically, pharmacokinetic/pharmacodynamic (PK/PD) analyses of drugs used in rodent PET studies are based on population average pharmacokinetic profiles of the drugs due to limited blood volume withdrawal while simultaneously maintaining physiological homeostasis. This likely results in bias of PET data quantification, including unknown bias of target occupancy (TO) measurements. This study aimed to develop a High Performance Liquid Chromatography (HPLC) method for PK/PD quantification of drugs used in preclinical rodent PET research, specifically the translocator 18&#8239;kDa protein (TSPO) selective drug, PK11195, that used sub-millilitre blood volumes. The lowest detection limit for the proposed HPLC method ranged between 7.5 and 10&#8239;ng/mL depending on the method used to calculate the limit of detection, and the measured average relative standard deviation for intermediate precision was equal to 17.2%. Most importantly, we were able to demonstrate a significant difference between calculated PK11195 concentrations at 0.5, 1, 2, 3, 5, 15 and 30&#8239;min post-administration and individually measured whole blood levels (significance level range from <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05 to <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.001; one-way ANOVA, Dunnet's post hoc test, p&#8239;&lt;&#8239;0.05). The HPLC method developed here uses sub-millilitre sample volumes to reproducibly assess PK/PD of PK11195 in rodent blood. This study highlights the importance of individually measured PK/PD drug concentrations when quantifying the TO from blocking/displacement rodent PET experiments.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><label>&#8226;</label><p id="p0005">A new HPLC method to measure low drug levels in blood and tissue was developed.</p></list-item><list-item id="li0010"><label>&#8226;</label><p id="p0010">This method uses sub-millilitre samples to reproducibly assess PK/PD of drugs.</p></list-item><list-item id="li0015"><label>&#8226;</label><p id="p0015">Population-based drug level curves overestimated real drug plasma levels.</p></list-item><list-item id="li0020"><label>&#8226;</label><p id="p0020">New HPLC method can be rapidly applied to rodent PET target-occupancy studies.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Abbreviations</title><kwd>PET, positron emission tomography</kwd><kwd>PK/PD, pharmacokinetics/pharmacodynamics</kwd><kwd>HPLC, high performance liquid chromatography</kwd><kwd>TO, target occupancy</kwd><kwd>TSPO, translocator 18&#8239;kDa protein</kwd></kwd-group><kwd-group id="ks0010"><title>Keywords</title><kwd>Positron emission tomography</kwd><kwd>PK/PD</kwd><kwd>HPLC</kwd><kwd>PK11195</kwd><kwd>Target occupancy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0025">Positron Emission Tomography (PET) is a molecular imaging modality with numerous applications in both preclinical and clinical research environment. This non-invasive technique offers great sensitivity allowing for <italic toggle="yes">in vivo</italic> imaging of biochemical processes by injecting a radioactive isotope-labelled compound at tracer levels (typically picomolar to micromolar range) [<xref rid="bb0005" ref-type="bibr">1</xref>]. One of the key applications of PET imaging is to support target-occupancy (TO) studies with newly developed drugs, i.e. to serve as a companion biomarker. Furthermore, TO studies can be pivotal at confirming selective target engagement of novel PET radiotracers [<xref rid="bb0010" ref-type="bibr">2</xref>]. In human clinical trials, the percentage TO quantification is supported by pharmacokinetic/pharmacodynamic (PK/PD) analysis of arterial or venous blood for each individual in order to determine plasma or whole blood levels of the blocking/displacement agent at a given time point [<xref rid="bb0015" ref-type="bibr">3</xref>,<xref rid="bb0020" ref-type="bibr">4</xref>]. Also, this approach has been extensively and directly applied to PET TO studies in large animals [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0030" ref-type="bibr">6</xref>]. Unfortunately, individual PK/PD analysis of drugs used in PET TO studies of small animals, specifically, rodents, is less standard [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0040" ref-type="bibr">8</xref>] and at best the impact of using population-based assessments in rodents is poorly described. Accurate quantification of PK/PD on an individual basis is rationally justified because technical errors during drug administration (e.g. faulty injection or partial volume injected), as well as individual variability in metabolism (e.g. due to either genetic or environmental factors [<xref rid="bb0045" ref-type="bibr">9</xref>]) cannot be adequately corrected if a population average PK/PD curve is used. Overcoming this bias would benefit accuracy of the preclinical PET TO image quantification and would facilitate confident selection of novel radiotracers and drugs suitable for further translational research.</p><p id="p0030">Foreseeably, the main limiting factors for implementing individual PK/PD analysis as standard practice in small animal PET studies are: (1) the extremely low levels of blocking or displacement agents concentration in the whole blood/plasma which might represent challenges in terms of detection limits of chromatographic instrumentation, such as high performance liquid chromatography (HPLC); and (2) most critically, the small blood sampling volume allowed for small animals [<xref rid="bb0050" ref-type="bibr">10</xref>]. Here we propose a rapid and practical analytical HPLC method which allows for detection of blood and tissue concentrations of a well-known selective 18&#8239;kDa translocator protein (TSPO) drug, PK11195 (1-[2-chlorophenyl]-N-[1-methyl-propyl]-3-isoquinoline carboxamide), in small (sub-mililitre) volumes of rat whole blood and tissue samples. Whole blood analysis was preferred over plasma analysis, as PK11195 is known to bind to erythrocytes and plasma proteins [<xref rid="bb0055" ref-type="bibr">11</xref>,<xref rid="bb0060" ref-type="bibr">12</xref>].</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>Reagents and solvents</title><p id="p0035">PK11195 (&gt;99% purity) was purchased from Abcam (Cambridge, UK). The gradient grade HiperSolv CHROMANORM&#174; acetonitrile (&gt;99.9% purity) was acquired from VWR Chemicals (Lutterworth, UK). The ultrapure water was obtained by using Millipore Smart2Pure water purification system. Prior to use, both acetonitrile and water were filtered through 0.22&#8239;&#956;m Magna nylon membranes (GVS, USA) using a chemical duty vacuum pump (Millipore, US). DMSO was purchased from Fisher Bioreagents (US).</p></sec><sec id="s0020"><label>2.2</label><title>Animals and sample collection</title><p id="p0040">All experiments were authorized by the local University of Edinburgh animal welfare and ethical review committee and were conducted in accordance with the Home Office Animals (Scientific Procedures) Act 1986. Healthy na&#239;ve adult male Sprague-Dawley rats (373&#8239;&#177;&#8239;20&#8239;g, mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;=&#8239;6) were anaesthetised using 2.0&#8211;2.5% isoflurane (50/50 oxygen/nitrous oxide, 1&#8239;L/min). The femoral artery was cannulated for blood collection post drug administration as described previously [<xref rid="bb0065" ref-type="bibr">13</xref>] and PK11195 (5&#8239;mg/kg in 100% DMSO, 100&#8239;&#956;L) was injected via tail vein (bolus i.v.). Animals have been divided into two groups: animals 1, 2 and 3 had their arterial blood samples taken at 0.5, 1, 2 and 3&#8239;min post-PK11195 injection; whereas animals 4, 5 and 6 had their arterial blood samples taken at 5, 15, 30 and 60&#8239;min post-PK11195 injection. In total, 4&#8239;mL of blood have been collected into heparinized tubes (50&#8239;IU/mL) from each animal, i.e. 1&#8239;mL per time point, in order to respect the blood volume collection limits for rats [<xref rid="bb0050" ref-type="bibr">10</xref>]. Immediately after, each 1&#8239;mL sample was sub-aliquot into 300&#8239;&#956;L samples for subsequent HPLC analysis. The tissue samples, including heart, lungs, brain and spleen were collected at a terminal point, i.e. 3&#8239;min (animals 1, 2, 3) and 60&#8239;min (animals 4, 5, 6) post-PK11195 injection. Following collection, both whole blood and tissue samples were frozen on dry ice and stored at &#8722;80&#8239;&#176;C until processed. Analysis of whole-blood samples rather than plasma processed samples is common place to drugs that bind to blood cells [<xref rid="bb0070" ref-type="bibr">14</xref>,<xref rid="bb0075" ref-type="bibr">15</xref>].</p></sec><sec id="s0025"><label>2.3</label><title>Analytical HPLC method development</title><sec id="s0030"><label>2.3.1</label><title>HPLC system and PK11195 detection</title><p id="p0045">HPLC analysis was performed on a Dionex Ultimate 3000 UHPLC (Thermo Scientific, UK). The chromatographic separation was carried out at 25&#8239;&#176;C using a Luna&#174; C18(2) 150&#8239;mm&#8239;&#215;&#8239;4.6&#8239;mm, 10&#8239;&#956;m column (Phenomenex, UK). The mobile phase consisted of 70% acetonitrile in water. A reference standard PK11195 sample has been prepared at 1&#8239;mg/mL concentration in acetonitrile:water (70:30). A 100&#8239;&#956;L sample of the PK11195 reference standard was injected and the column was eluted with an isocratic mobile phase (1&#8239;mL/min flow for 10&#8239;min). The peak of PK11195 in the samples was detected by UV/Vis detector at 331&#8239;nm.</p></sec><sec id="s0035"><label>2.3.2</label><title>Chromatographic method validation</title><p id="p0050">In order to test the validity of the analytical HPLC method, the HPLC method repeatability and intermediate precision, linearity, limit of detection (LOD) and limit of quantitation (LOQ) were calculated.</p><p id="p0055">In order to determine the linearity of the method, the calibration curve of PK11195 was generated by injecting freshly prepared PK11195 dissolved in acetonitrile:water (70:30) (concentration range 7.5&#8211;1000&#8239;ng/mL, <italic toggle="yes">n</italic>&#8239;=&#8239;3 per concentration) using the analytical HPLC method described in <xref rid="s0030" ref-type="sec">Section 2.3.1</xref>. The concentration was plotted versus the average peak area. The two lowest concentrations at which the PK11195 peak could be visually identified (7.5 and 25&#8239;ng/mL) and two concentrations in between (10 and 15&#8239;ng/mL) were selected for analysis of system repeatability and injected onto the HPLC system 6 consecutive times using the same conditions. The experiment was repeated on another day for intermediate precision testing. Measuring system repeatability and intermediate precision at concentrations around the LOD/LOQ values provides additional confidence on the robustness of the obtained measures, as the analysis of the samples around these working limits are more challenging and represent worst-case conservative scenario. Both repeatability and intermediate precision were expressed as percentage relative standard deviation (%RSD). The LOD and LOQ for the proposed HPLC method were calculated as previously described [<xref rid="bb0080" ref-type="bibr">16</xref>] and using the formulae:<disp-formula id="fo0005"><label>(1)</label><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:mi>LOD</mml:mi><mml:mo>=</mml:mo><mml:mn>3.3</mml:mn><mml:mo>&#215;</mml:mo><mml:mfrac><mml:mi mathvariant="normal">&#963;</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:mfrac></mml:math></disp-formula><disp-formula id="fo0010"><label>(2)</label><mml:math id="M2" altimg="si2.gif" overflow="scroll"><mml:mi>LOQ</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mo>&#215;</mml:mo><mml:mfrac><mml:mi mathvariant="normal">&#963;</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:mfrac></mml:math></disp-formula>where, <italic toggle="yes">&#963;</italic> is the standard deviation of the y-intercept, and <italic toggle="yes">S</italic> is the slope of the calibration curve. Additionally, LOD was determined by calculating signal to noise ratio and peak detectability was defined as a S/N ratio &gt;2, according to the International Council for Harmonisation (ICH) standards [<xref rid="bb0085" ref-type="bibr">17</xref>].</p></sec></sec><sec id="s0040"><label>2.4</label><title>PK11195 PK/PD measurements in rat blood and tissue</title><sec id="s0045"><label>2.4.1</label><title>Blood and tissue sample preparation and HPLC analysis</title><p id="p0060">On the day of the HPLC experiment, ultrapure water was added to the defrosted tissue samples (heart, lungs and spleen 1:1, w/v; and brain 1:3, w/v) in order to facilitate homogenization. The homogenized tissues and arterial blood samples were centrifuged at 2000&#8239;rpm 4&#8239;&#176;C (24 position rotor, Heraeus Megafuge 8R, Thermo Scientific) for 5&#8239;min. The whole blood and tissue supernatants were collected and centrifugation was repeated 3 times under the same conditions in order to recover as much whole blood and tissue supernatant as possible. Freezing-thawing cycle of the whole blood sample causes cell lysis, therefore the resultant supernatant represents the whole blood drug content, in line with previously described blood sample collection and storage/processing methods [<xref rid="bb0090" ref-type="bibr">18</xref>,<xref rid="bb0095" ref-type="bibr">19</xref>]. The cell-free tissue and whole blood and tissue supernatants were denatured using acetonitrile (1:1.4, v/v) and centrifuged at 2000&#8239;rpm 4&#8239;&#176;C for 4&#8239;min. Following protein precipitation, the final supernatants were collected for HPLC analysis.</p><p id="p0065">The prepared samples were analysed using the method described in <xref rid="s0030" ref-type="sec">Section 2.3.1</xref>. The measured PK11195 peak area was converted to concentration by applying linear regression equation obtained from the calibration curve.</p></sec><sec id="s0050"><label>2.4.2</label><title>Comparison of calculated versus measured PK11195 concentration in rat whole blood</title><p id="p0070">It was important to assess how accurate the calculated PK11195 concentrations were relative to measured PK11195 concentration using the HPLC method described in this study. The results obtained from the analysed blood samples collected at 0.5, 1, 2, 3, 5, 15, 30 and 60&#8239;min after the administration of PK11195 were compared to the concentration of PK11195 estimated from the two-phase exponential regression equation (Eq. <xref rid="fo0015" ref-type="disp-formula">3</xref>) derived from the population-based blood PK/PD curve.</p></sec></sec><sec id="s0055"><label>2.5</label><title>Statistical analysis and PK/PD data fitting</title><p id="p0075">Statistical analysis of the results was performed using GraphPad Prism 5 (GraphPad Software, USA). Statistical significance was estimated by one-way ANOVA followed by Bonferroni or Dunnett's post-hoc tests. One-phase decay exponential regression model was applied to determine PK/PD of PK11195 in individual animals, and two-phase decay exponential regression model was applied in order to estimate the population pharmacokinetic whole blood profile of PK11195.</p></sec></sec><sec id="s0060"><label>3</label><title>Results</title><sec id="s0065"><label>3.1</label><title>Analytical HPLC method development</title><p id="p0080">The average PK11195 retention time (<italic toggle="yes">t</italic>R) was 5.18&#8239;&#177;&#8239;0.04&#8239;min (mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;=&#8239;80 different injections used for method development, <xref rid="f0005" ref-type="fig">Fig. 1</xref>A). Collected data showed the HPLC signal measured with the developed method was linear relative to the sample concentration (<italic toggle="yes">r</italic><sup><italic toggle="yes">2</italic></sup>&#8239;=&#8239;0.999, <xref rid="f0005" ref-type="fig">Fig. 1</xref>B) and the fitting residuals were&#8239;&#177;&#8239;0.005 mAU&#183;min (<xref rid="f0005" ref-type="fig">Fig. 1</xref>C) with only two outliers outside the 95% confidence interval correspondent to concentrations 100&#8239;ng/mL and 500&#8239;ng/mL. The measured method repeatability on day 1 and 2 was 11.3% and 9.5% on average, respectively. The mean value for the intermediate precision was 17.3% (<xref rid="t0005" ref-type="table">Table 1</xref>).<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Linearity of the proposed analytical HPLC method. A) Representative chromatogram of PK11195 1000&#8239;ng/mL (<italic toggle="yes">t</italic><sub><italic toggle="yes">R</italic></sub>&#8239;=&#8239;5.19&#8239;min). B) Calibration curve of PK11195 (concentration range 7.5&#8211;1000&#8239;ng/mL; <italic toggle="yes">n</italic>&#8239;=&#8239;3 per concentration, &#177;95% CI shown as data points error bars). Linear equation: Y&#8239;=&#8239;0.0006&#215;&#8239;+&#8239;0.0073, where Y&#8239;=&#8239;response (mAU&#183;min), x&#8239;=&#8239;PK11195 concentration (ng/mL), <italic toggle="yes">r</italic><sup><italic toggle="yes">2</italic></sup>&#8239;=&#8239;0.999. C) Residuals plot of the calibration curve and 95% CI shown as dashed lines. CI&#8239;=&#8239;confidence interval.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Measured HPLC peak area for different PK11195 concentrations, repeatability and reproducibility of the developed analytical method. All data shown as average response&#177;SD (<italic toggle="yes">n</italic>&#8239;=&#8239;6), D1&#8239;=&#8239;the 1st day of sample analysis and D2&#8239;=&#8239;the 2nd day of sample analysis.</p></caption><alt-text id="al0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="4" rowspan="1">Concentration of PK11195<hr/></th></tr><tr><th colspan="1" rowspan="1">7.5&#8239;ng/mL</th><th colspan="1" rowspan="1">10&#8239;ng/mL</th><th colspan="1" rowspan="1">15&#8239;ng/mL</th><th colspan="1" rowspan="1">25&#8239;ng/mL</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Average response D1 (mAU&#183;min)</td><td colspan="1" rowspan="1">0.010&#8239;&#177;&#8239;0.002</td><td colspan="1" rowspan="1">0.011&#8239;&#177;&#8239;0.001</td><td colspan="1" rowspan="1">0.012&#8239;&#177;&#8239;0.002</td><td colspan="1" rowspan="1">0.020&#8239;&#177;&#8239;0.003</td></tr><tr><td colspan="1" rowspan="1">Repeatability D1 (%)</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Average response D2 (mAU&#183;min)</td><td colspan="1" rowspan="1">0.009&#8239;&#177;&#8239;0.001</td><td colspan="1" rowspan="1">0.010&#8239;&#177;&#8239;0.001</td><td colspan="1" rowspan="1">0.013&#8239;&#177;&#8239;0.001</td><td colspan="1" rowspan="1">0.023&#8239;&#177;&#8239;0.001</td></tr><tr><td colspan="1" rowspan="1">Repeatability D2 (%)</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Intermediate precision D1 vs. D2 (%)</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">17</td></tr></tbody></table></table-wrap></p><p id="p0085">The calculated LOD for the present analytical HPLC method was 11.7&#8239;ng/mL, and LOQ was equal to 35.4&#8239;ng/mL when determined using standard equations (Eq. <xref rid="fo0005" ref-type="disp-formula">(1)</xref>, <xref rid="fo0010" ref-type="disp-formula">(2)</xref>). The S/N ratio analysis showed this ratio was higher than 2 for all the PK11195 concentrations tested: 2.4&#8239;&#177;&#8239;0.6 for 7.5&#8239;ng/mL, 3.0&#8239;&#177;&#8239;0.5 for 10&#8239;ng/mL, 3.1&#8239;&#177;&#8239;0.4 for 15&#8239;ng/mL and 4.5&#8239;&#177;&#8239;0.5 for 25&#8239;ng/mL (mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;=&#8239;12).</p></sec><sec id="s0070"><label>3.2</label><title>PK11195 PK/PD measurements in rat blood and tissue</title><p id="p0090">In order to test the feasibility and reproducibility of the proposed analytical HPLC method with sub-millilitre injection volumes of biological samples containing PK11195, upon collection, each 1&#8239;mL whole blood sample was divided into three equal volumes (i.e. 3 x ~300&#8239;&#956;L), frozen for storage, then defrosted, centrifuged and denatured to obtain supernatant and analysed using HPLC. Each one out of three 300&#8239;&#956;L whole blood samples was processed and analysed on a different day during the course of three days. On average, the inter-sample variability was 15.5% (<xref rid="t0010" ref-type="table">Table 2</xref>), in line with inter-day variability assessed using reference standard solutions of PK11195. The retention time of PK11195 in whole blood and tissue samples remained consistent throughout the study (5.18&#8239;&#177;&#8239;0.03&#8239;min, <italic toggle="yes">n</italic>&#8239;=&#8239;94) and it was identical to the retention time of the reference standard.<table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Inter-sample PK/PD variability of PK11195 in biological samples. Average PK11195 whole blood concentration&#8239;&#177;&#8239;SD at different time points post-PK11195 injection for individual animals (<italic toggle="yes">n</italic>&#8239;=&#8239;2 for 5&#8239;min whole blood samples from animals 5 and 6, and <italic toggle="yes">n</italic>&#8239;=&#8239;3 for all remaining time points per animal) were measured using the proposed analytical HPLC method. The level of significance in the sample group (i.e. PK11195 concentration at particular time point across three animals) was determined using one-way ANOVA followed by Bonferroni's post hoc test (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05).</p></caption><alt-text id="al0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Time, min</th><th colspan="1" rowspan="1">PK11195 (ng/mL)</th><th colspan="1" rowspan="1">RSD, %</th><th colspan="1" rowspan="1">PK11195 (ng/mL)</th><th colspan="1" rowspan="1">RSD, %</th><th colspan="1" rowspan="1">PK11195 (ng/mL)</th><th colspan="1" rowspan="1">RSD, %</th><th colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"/><td colspan="2" align="center" rowspan="1"><italic toggle="yes">Animal 1</italic></td><td colspan="2" align="center" rowspan="1"><italic toggle="yes">Animal 2</italic></td><td colspan="2" align="center" rowspan="1"><italic toggle="yes">Animal 3</italic></td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">895&#8239;&#177;&#8239;47</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">702&#8239;&#177;&#8239;135</td><td colspan="1" rowspan="1">19.2</td><td colspan="1" rowspan="1">467&#8239;&#177;&#8239;29</td><td colspan="1" rowspan="1">6.1</td><td colspan="1" rowspan="1">0.0067</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">762&#8239;&#177;&#8239;49</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">388&#8239;&#177;&#8239;70</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">395&#8239;&#177;&#8239;39</td><td colspan="1" rowspan="1">9.8</td><td colspan="1" rowspan="1">0.0007</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">682&#8239;&#177;&#8239;64</td><td colspan="1" rowspan="1">9.3</td><td colspan="1" rowspan="1">357&#8239;&#177;&#8239;50</td><td colspan="1" rowspan="1">13.8</td><td colspan="1" rowspan="1">327&#8239;&#177;&#8239;36</td><td colspan="1" rowspan="1">11.1</td><td colspan="1" rowspan="1">0.0008</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">627&#8239;&#177;&#8239;42</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">313&#8239;&#177;&#8239;23</td><td colspan="1" rowspan="1">7.3</td><td colspan="1" rowspan="1">292&#8239;&#177;&#8239;5</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="2" align="center" rowspan="1"><italic toggle="yes">Animal 4</italic></td><td colspan="2" align="center" rowspan="1"><italic toggle="yes">Animal 5</italic></td><td colspan="2" align="center" rowspan="1"><italic toggle="yes">Animal 6</italic></td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">93&#8239;&#177;&#8239;47</td><td colspan="1" rowspan="1">50.4</td><td colspan="1" rowspan="1">488;415</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">240; 215</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">0.0034</td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">73&#8239;&#177;&#8239;33</td><td colspan="1" rowspan="1">45.4</td><td colspan="1" rowspan="1">259&#8239;&#177;&#8239;19</td><td colspan="1" rowspan="1">7.3</td><td colspan="1" rowspan="1">138&#8239;&#177;&#8239;7</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">0.0005</td></tr><tr><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">48&#8239;&#177;&#8239;3</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">144&#8239;&#177;&#8239;16</td><td colspan="1" rowspan="1">11.1</td><td colspan="1" rowspan="1">94&#8239;&#177;&#8239;7</td><td colspan="1" rowspan="1">7.6</td><td colspan="1" rowspan="1">0.0003</td></tr><tr><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">35&#8239;&#177;&#8239;24</td><td colspan="1" rowspan="1">69.6</td><td colspan="1" rowspan="1">52&#8239;&#177;&#8239;10</td><td colspan="1" rowspan="1">18.5</td><td colspan="1" rowspan="1">48&#8239;&#177;&#8239;11</td><td colspan="1" rowspan="1">22.6</td><td colspan="1" rowspan="1">0.5791</td></tr></tbody></table></table-wrap></p><p id="p0095"><xref rid="f0010" ref-type="fig">Fig. 2</xref> presents the PK/PD response of PK11195 in rat whole blood over time. Measured half-life (<italic toggle="yes">T</italic><sub><italic toggle="yes">1/2</italic></sub>) for animal 1, 2 and 3 were 0.6&#8239;min, 0.2&#8239;min and 0.8&#8239;min, respectively. Area under the curve (AUC) for animals 1, 2 and 3 were 1790, 980.8 and 886.1&#8239;ng/mL&#183;min, respectively (<xref rid="f0010" ref-type="fig">Fig. 2</xref>A). Measured <italic toggle="yes">T</italic><sub><italic toggle="yes">1/2</italic></sub> for animals 4, 5 and 6 were 15.9&#8239;min, 11.9&#8239;min and 12.2&#8239;min, respectively. Area under the curve (AUC) for animals 4, 5 and 6 were 2989, 9516 and 5709&#8239;ng/mL&#183;min, respectively (<xref rid="f0010" ref-type="fig">Fig. 2</xref>B). By combining the data obtained from all individual animals in the study and by applying two-phase exponential regression model to this data set, a population average curve was obtained (<xref rid="f0010" ref-type="fig">Fig. 2</xref>C) and an equation was derived, which can be used to determine PK11195 concentration in rat whole blood at any given time point:<disp-formula id="fo0015"><label>(3)</label><mml:math id="M3" altimg="si3.gif" overflow="scroll"><mml:mfenced open="[" close="]"><mml:mrow><mml:mi mathvariant="italic">PK</mml:mi><mml:mn>11195</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>7.8</mml:mn><mml:mo>+</mml:mo><mml:mn>523.2</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>0.4</mml:mn><mml:mi mathvariant="italic">time</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>222.4</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>0.03</mml:mn><mml:mi mathvariant="italic">time</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula><fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Individual and population-based PK/PD curves of PK11195 in rat whole blood. A) One-phase exponential regression plot representing the concentration of PK11195 in the whole blood at 0.5, 1, 2, 3&#8239;min post-intravenous administration of the animals 1, 2, 3 and B) 5, 15, 30 and 60&#8239;min post-injection of the animals 4, 5, 6 (mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;<italic toggle="yes">=</italic>&#8239;<italic toggle="yes">3</italic> per time point). C) Measured whole blood PK11195 concentrations at 0.5, 1, 2, 3, 5, 15, 30 and 60&#8239;min post-injection in the animals 1 to 6, represented by black dots and error bars (mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;<italic toggle="yes">=</italic>&#8239;<italic toggle="yes">3</italic> per time point), and population-based two-phase exponential regression plot (red dotted line) representing the calculated concentration of PK11195 in the whole blood over time. This regression plot was used to derive Eq. <xref rid="fo0015" ref-type="disp-formula">3</xref>.</p><p>Statistically significant differences were determined using ANOVA, Bonferroni Post-hoc test, <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05(*), <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.01(**). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0100">The calculated PK11195 concentration from the population average curve was compared with the measured PK11195 concentration in rat whole blood at 0.5, 1, 2, 3, 5, 15, 30 and 60&#8239;min post-injection (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). The results showed that the PK11195 concentration obtained using Eq. <xref rid="fo0015" ref-type="disp-formula">3</xref> was significantly different from measured PK11195 concentration in at least one animal at every time point, with the exception of samples collected at 60&#8239;min post-injection, (one-way ANOVA followed by Dunnetts' multiple comparison test, <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05).<fig id="f0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Comparison of calculated versus measured concentration of PK11195 in whole blood. Calculated vs measured PK11195 concentration in rodent whole blood at 0.5&#8239;min (A), 1&#8239;min (B), 2&#8239;min (C), and 3&#8239;min (D) post-injection of PK11195 (mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;=&#8239;3, one-way ANOVA followed by Dunnetts' multiple comparison test (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05)). Calculated vs measured PK11195 concentration in rodent blood at 5&#8239;min (E), 15&#8239;min (F), 30&#8239;min (G), and 60&#8239;min (H) post-injection of PK11195 (mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;=&#8239;3, one-way ANOVA followed by Dunnetts' multiple comparison test (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05)). p&#8239;&lt;&#8239;0.05(*), p&#8239;&lt;&#8239;0.01(**), <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.001(***).</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0105">The developed HPLC method was also applied to investigate concentration of PK11195 in tissue. The PK/PD analysis showed that PK11195 was actively and rapidly cleared from the blood and kinetically transferred into the organs (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). The average PK11195 concentration was not significantly different at 3&#8239;min post-injection across all the organs tested in the study (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A), however 1&#8239;h post-injection the drug levels in the brain were significantly lower when compared to the heart, lungs and spleen as well as lower in the spleen when compared to the lungs (<italic toggle="yes">p</italic>&#8239;=&#8239;0.0003; one-way ANOVA, Bonferroni multiple comparison test).<fig id="f0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Concentration of PK11195 in the different tissues. The concentration of PK11195 across different organs at A) 3&#8239;min and B) 60&#8239;min post-injection. Results presented as mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;=&#8239;3. Statistically significant differences were determined using one-way ANOVA followed by Bonferroni multiple comparison test, <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05(*), <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.01(**), <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.001(***).</p></caption><alt-text id="al0020">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec></sec><sec id="s0075"><label>4</label><title>Discussion</title><p id="p0110">In this study, an analytical HPLC method was developed for the detection of nanomolar concentrations of the TSPO selective drug, PK11195, in small size biological samples. The developed method has shown to be feasible, reproducible and linear. Robustness of the method was successfully challenged with nanomolar concentrations and sub-millilitre volumes. Results presented here highlight and quantify the bias associated with population-based PK/PD analysis versus individual analysis of small animal data, with consequent impact on drug studies, namely PET TO data quantification. Even though the described HPLC method is valid only for PK11195, upon developing appropriate HPLC methods, the same approach could be potentially applied for testing PK/PD of different drugs.</p><p id="p0115">The proposed analytical HPLC method for PK11195 detection proved to be feasible using both chemical and biological samples (whole blood and tissue). On average, the method repeatability was 17.3% for chemical PK11195 dilutions and 13.5% for whole blood samples containing tracer amounts of PK11195. A 5 to 15% repeatability limit in chromatographic measurements has been defined for analysis at trace levels [<xref rid="bb0100" ref-type="bibr">20</xref>], and even though the average intermediate precision among PK11195 measurements in chemical samples was higher than this limit, the value for PK11195 detection in blood samples was within the required range (<xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="t0010" ref-type="table">Table 2</xref>). Other validation criteria were met as the method showed exceptionally good linearity even at LOD, which was at nanomolar range. Our results are in line with previously published data indicating that, in chromatographic analysis, smaller values of the detection limit and the quantification limit were better described by visual analysis or S/N ratio, albeit larger variations [<xref rid="bb0105" ref-type="bibr">21</xref>]. Furthermore, we have quantified the S/N ratio for the peaks observed in the HPLC trace at the four lowest concentrations, as an additional line of evidence to test the sensitivity of the method. That analysis has shown the LOD was 7.5&#8239;ng/mL with a S/N ratio of 2.4&#8239;&#177;&#8239;0.6 (mean&#8239;&#177;&#8239;SD, <italic toggle="yes">n</italic>&#8239;=&#8239;12). Taken together, all this criteria pinpoint the developed HPLC method as a reproducible and sensitive analytical tool for PK11195 levels above 7.5&#8239;ng/mL.</p><p id="p0120">Previously described methods for HPLC analysis of PK11195 were overall similar to the method proposed in this study, but there was a large range of HPLC mobile phases and UV wavelengths used for PK11195 elution and detection. The UV light wavelengths ranged from 254&#8239;nm to 310&#8239;nm, and organic solvent:water ratio of the mobile phase ranged between 30:70 to 80:20 [<xref rid="bb0110" ref-type="bibr">[22]</xref>, <xref rid="bb0115" ref-type="bibr">[23]</xref>, <xref rid="bb0120" ref-type="bibr">[24]</xref>]. Using our chromatographic system, and after testing a wide range of UV wavelengths, we concluded that the optimal wavelength to detect PK11195 in biological samples was 331&#8239;nm (data not shown). In 2008, Wala et al. [<xref rid="bb0125" ref-type="bibr">25</xref>] has also described a HPLC method of PK11195 detection and PK/PD analysis in rats. They have reported PK11195 detection at 240&#8239;nm UV channel using K&#8322;HPO&#8324;:methanol:acetonitrile (35:63:2) as mobile phase and Supelco LC-8 column with a retention time twice as long as the one obtained with our method (<italic toggle="yes">tR</italic>&#8239;=&#8239;10&#8239;min versus <italic toggle="yes">tR</italic>&#8239;=&#8239;5.18&#8239;min). Even though %RSD for repeatability and reproducibility at 500&#8239;ng/mL PK11195 were 7.7% and 7.9%, respectively, it is worth noting that the concentration used by the authors was 50&#8211;65 fold higher than the concentrations used for repeatability and intermediate precision testing using our method, hence more favourable %RSD values. Despite these differences, the LOD was 10&#8239;ng/mL. Therefore, the results reported in the current study are comparable with the findings of Wala et al. in spite of the different methods used for blood processing. This is likely due to the known reversible PK11195 binding to erythrocytes and plasma proteins &#8211; albumin and &#945;1-acid glycoprotein [<xref rid="bb0055" ref-type="bibr">11</xref>,<xref rid="bb0060" ref-type="bibr">12</xref>]. As the PK11195 in plasma binds to tissues, the erythrocyte-bound and plasma protein-bound PK11195 may dissociate, causing fluctuations in plasma PK11195 levels. As a result, equilibrium between free and bound PK11195 levels is never reached. This justifies the use of whole blood drug for the HPLC analysis, as ultimately PK11195 present in whole blood contributes to the extent of its effects. Furthermore, other previously reported HPLC studies of drugs that are known to bind to the red blood cells have also used whole blood measurements and reported a blood collection and storage method similar the one described in this manuscript [<xref rid="bb0090" ref-type="bibr">18</xref>,<xref rid="bb0095" ref-type="bibr">19</xref>].</p><p id="p0125">Most importantly, we were also able to demonstrate that the usage of population average PK/PD data of PK11195 for rodent PET TO image quantification can result in notable quantitative bias (0.3 to 1.7 fold difference between calculated and measured PK11195 whole blood levels). The larger inter-individual variability is likely to be a result of operational artefacts and individual variability in metabolism in different animals. Still, this issue can be overcome by applying the proposed analytical HPLC method as standard PK/PD determination test, in order to improve the accuracy of the preclinical PET TO data quantification and accelerate confident translation of novel radiotracers and drugs from the preclinical to clinical research. PET TO small animal studies play an important role in the early phase drug development, as they assist dosing regimen optimisation for subsequent clinical trials [<xref rid="bb0130" ref-type="bibr">[26]</xref>, <xref rid="bb0135" ref-type="bibr">[27]</xref>, <xref rid="bb0140" ref-type="bibr">[28]</xref>]. Therefore, the adherence to individual-based PK/PD analysis, such as the one reported here, would significantly improve the accuracy of preclinical PET TO quantification, and consequently supports the translational process.</p><p id="p0130">Even though there are other slightly more sensitive chromatographic systems for PK11195 detection available, such as LC/MS [<xref rid="bb0145" ref-type="bibr">[29]</xref>, <xref rid="bb0150" ref-type="bibr">[30]</xref>, <xref rid="bb0155" ref-type="bibr">[31]</xref>], our proposed method proved to be relatively inexpensive, rapid and reliable. The adherence to this individual approach could be rapidly realised across laboratories. Another advantage of the developed method is that the small blood sample size of approximately 300&#8239;&#956;L is sufficient for the robust analysis. It offers the opportunity for reliable quantitative PK/PD analysis of PK11195 in smaller species.</p><p id="p0135">In addition to whole blood data, in this study we have also demonstrated that it is possible to detect PK11195 in rodent tissues, such as heart, lungs, brain and spleen, using the proposed sample processing and analytical HPLC methods. The data becomes extremely useful when determining a direct relationship between blocking drug concentration and percentage occupancy in the target tissue during preclinical PET radiotracer development process and early preclinical phases of drug discovery. Even though in the clinical drug development environment there is no readily available access to tissue [<xref rid="bb0160" ref-type="bibr">32</xref>], given the ability of the proposed HPLC method to perform well even with small quantities (sub-millilitre) blood samples, this approach could potentially be applied for small human tissue samples obtained during tissue biopsy procedures.</p></sec><sec id="s0080"><label>5</label><title>Conclusions</title><p id="p0140">A robust chromatographic method to measure PK11195 concentration in small volume rodent whole blood samples and tissue was developed. This method uses sub-millilitre sample volumes to rapidly and reproducibly assess PK/PD of PK11195 in small animals. Data collected highlighted the need for individually measured PK/PD drug concentration levels in samples, in order to derive more accurate drug exposure levels compared with population-based estimates often used in preclinical research with small animals. Even though different HPLC methods would have to be developed for different drugs, this proof-of-concept study using PK11195 suggests that the proposed methodological approach is feasible even with sub-millilitre volumes and, if applied more widely, has potential to help eliminate the bias in small animal TO PET data quantification.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name name-style="western"><surname>Phelps</surname><given-names>M.E.</given-names></name></person-group><article-title>Positron emission tomography provides molecular imaging of biological processes</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>97</volume><year>2000</year><fpage>9226</fpage><lpage>9233</lpage><pub-id pub-id-type="pmid">10922074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.97.16.9226</pub-id><pub-id pub-id-type="pmcid">PMC16850</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name name-style="western"><surname>Van De Bittner</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Ricq</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Hooker</surname><given-names>J.M.</given-names></name></person-group><article-title>A philosophy for CNS radiotracer design</article-title><source>Acc. Chem. Res.</source><volume>47</volume><year>2014</year><fpage>3127</fpage><lpage>3134</lpage><pub-id pub-id-type="pmid">25272291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ar500233s</pub-id><pub-id pub-id-type="pmcid">PMC4204929</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name name-style="western"><surname>Zamuner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rabiner</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Bani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Gomeni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ratti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>V.J.</given-names></name></person-group><article-title>A pharmacokinetic PET study of NK1 receptor occupancy</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><volume>39</volume><year>2012</year><fpage>226</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">21993526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-011-1954-2</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name name-style="western"><surname>Vandenhende</surname><given-names>F.</given-names></name><name name-style="western"><surname>Renard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tauscher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Witcher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D.F.</given-names></name></person-group><article-title>Bayesian hierarchical modeling of receptor occupancy in PET trials</article-title><source>J. Biopharm. Stat.</source><volume>18</volume><year>2008</year><fpage>256</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">18327720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10543400701697158</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name name-style="western"><surname>Hjorth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jucaite</surname><given-names>A.</given-names></name><name name-style="western"><surname>Varn&#228;s</surname><given-names>K.</given-names></name><name name-style="western"><surname>W&#228;hlby Hamr&#233;n</surname><given-names>U.</given-names></name><name name-style="western"><surname>Johnstr&#246;m</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guly&#225;s</surname><given-names>B.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Pike</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Halldin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Farde</surname><given-names>L.</given-names></name></person-group><article-title>A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates</article-title><source>Neuropharmacology</source><volume>101</volume><year>2016</year><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">25791528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2015.03.002</pub-id><pub-id pub-id-type="pmcid">PMC4678037</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name name-style="western"><surname>Varnas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jureus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnstrom</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ahlgren</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schott</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jerning</surname><given-names>E.</given-names></name><name name-style="western"><surname>Malmborg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Halldin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Afzelius</surname><given-names>L.</given-names></name><name name-style="western"><surname>Farde</surname><given-names>L.</given-names></name></person-group><article-title>Integrated strategy for use of positron emission tomography in nonhuman primates to confirm multitarget occupancy of novel psychotropic drugs: an example with AZD3676</article-title><source>J. Pharmacol. Exp. Ther.</source><volume>358</volume><year>2016</year><fpage>464</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">27402278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.116.234146</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name name-style="western"><surname>Nakatani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tokunaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoshinaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takenaka</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Suhara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>M.</given-names></name></person-group><article-title>A small-animal pharmacokinetic/pharmacodynamic PET study of central serotonin 1A receptor occupancy by a potential therapeutic agent for overactive bladder</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0075040</pub-id><pub-id pub-id-type="pmcid">PMC3781034</pub-id><pub-id pub-id-type="pmid">24086433</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name name-style="western"><surname>Parente</surname><given-names>A.</given-names></name><name name-style="western"><surname>Feltes</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Vallez Garcia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sijbesma</surname><given-names>J.W.A.</given-names></name><name name-style="western"><surname>Moriguchi Jeckel</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Dierckx</surname><given-names>R.A.J.O.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>E.F.J.</given-names></name><name name-style="western"><surname>Doorduin</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetic analysis of 11C-PBR28 in the rat model of herpes encephalitis: comparison with (R)-11C-PK11195</article-title><source>J. Nucl. Med.</source><volume>57</volume><year>2016</year><fpage>785</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">26823567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.115.165019</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name name-style="western"><surname>Daublain</surname><given-names>P.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nofsinger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Northrup</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Tschirret-Guth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cartwright</surname><given-names>M.</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>C.</given-names></name></person-group><article-title>Analyzing the potential root causes of variability of pharmacokinetics in preclinical species</article-title><source>Mol. Pharm.</source><volume>14</volume><year>2017</year><fpage>1634</fpage><lpage>1645</lpage><pub-id pub-id-type="pmid">28329443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.6b01118</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name name-style="western"><surname>Diehl</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Hull</surname><given-names>R.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rabemampianina</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Van De Vorstenbosch</surname><given-names>C.</given-names></name></person-group><article-title>A good practice guide to the administration of substances and removal of blood, including routes and volumes</article-title><source>J. Appl. Toxicol.</source><volume>21</volume><year>2001</year><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11180276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jat.727</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>J.M.M.</given-names></name><name name-style="western"><surname>Ciliax</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.B.</given-names></name></person-group><article-title>Presence of peripheral-type benzodiazepine binding sites on human erythrocyte membranes</article-title><source>Eur. J. Pharmacol.</source><volume>152</volume><year>1988</year><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">2850202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0014-2999(88)90834-5</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name name-style="western"><surname>Lockhart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rahmoune</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Earnshaw</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name></person-group><article-title>The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant &#945;1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker</article-title><source>Nucl. Med. Biol.</source><volume>30</volume><year>2003</year><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">12623120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0969-8051(02)00410-9</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name name-style="western"><surname>Warnock</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bahri</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Goblet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giacomelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lemaire</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seret</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langlois</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luxen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Plenevaux</surname><given-names>A.</given-names></name></person-group><article-title>Use of a beta microprobe system to measure arterial input function in PET via an arteriovenous shunt in rats</article-title><source>EJNMMI Res.</source><volume>1</volume><year>2011</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2191-219X-1-13</pub-id><pub-id pub-id-type="pmcid">PMC3250971</pub-id><pub-id pub-id-type="pmid">22214227</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="book" id="rf0070"><person-group person-group-type="author"><name name-style="western"><surname>Blomback</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blomback</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hessel</surname><given-names>B.</given-names></name></person-group><chapter-title>Mechanism of Haemolysis Caused by Freezing and its Prevention</chapter-title><volume>vol. 193</volume><year>1962</year><fpage>884</fpage><lpage>885</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/193884a0</pub-id><pub-id pub-id-type="pmid">13913934</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name name-style="western"><surname>Lovelock</surname><given-names>J.E.</given-names></name></person-group><article-title>The haemolysis of human red blood cells by freezing and thawing</article-title><source>Biochem. Biophys. Acta.</source><volume>10</volume><year>1953</year><fpage>414</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">13058999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-3002(53)90273-x</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name name-style="western"><surname>Chonkar</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Managuli</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Udupa</surname><given-names>N.</given-names></name></person-group><article-title>Development and validation of reversed phase high-performance liquid chromatography method for estimation of lercanidipine HCl in pure form and from nanosuspension formulation</article-title><source>J. Basic Clin. Pharm.</source><volume>7</volume><year>2015</year><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">26792958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0976-0105.170586</pub-id><pub-id pub-id-type="pmcid">PMC4702276</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name name-style="western"><surname>Shrivastava</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name></person-group><article-title>Methods for the determination of limit of detection and limit of quantitation of the analytical methods</article-title><source>Chronicles Young Sci</source><volume>2</volume><year>2011</year><fpage>21</fpage></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>HPLC determination and pharmacokinetic study of indapamide in human whole blood</article-title><source>Chromatographia</source><volume>61</volume><year>2005</year><fpage>581</fpage><lpage>585</lpage></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name name-style="western"><surname>Griffith</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Body</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mcdowell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keevil</surname><given-names>B.G.</given-names></name></person-group><article-title>Development of a method to measure plasma and whole blood choline by liquid chromatography tandem mass spectrometry</article-title><source>Ann. Clin. Biochem.</source><volume>47</volume><year>2010</year><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">19837724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1258/acb.2009.008191</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name name-style="western"><surname>Bose</surname><given-names>A.</given-names></name></person-group><article-title>HPLC calibration process parameters in terms of system suitability test</article-title><source>Austin Chromatogr</source><volume>1</volume><year>2014</year><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name name-style="western"><surname>Ribani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Bottoli</surname><given-names>C.B.G.</given-names></name></person-group><article-title>Validation of chromatographic methods: evaluation of detection and quantification limits in the determination of impurities in omeprazole</article-title><source>J. Chromatogr. A</source><volume>1156</volume><year>2007</year><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">17270195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chroma.2006.12.080</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name name-style="western"><surname>Ju&#269;aite</surname><given-names>A.</given-names></name><name name-style="western"><surname>Csel&#233;nyi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Arvidsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#197;hlberg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Julin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varn&#228;s</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stenkrona</surname><given-names>P.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Halldin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Farde</surname><given-names>L.</given-names></name></person-group><article-title>Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects</article-title><source>EJNMMI Res.</source><volume>2</volume><year>2012</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">22524272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2191-219X-2-15</pub-id><pub-id pub-id-type="pmcid">PMC3350394</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name name-style="western"><surname>Yankam Njiwa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Costes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bouillot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouvard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fieux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Levigoureux</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kocevar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stamile</surname><given-names>C.</given-names></name><name name-style="western"><surname>Langlois</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Bolbos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bezin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hammers</surname><given-names>A.</given-names></name></person-group><article-title>Quantitative longitudinal imaging of activated microglia as a marker of inflammation in the pilocarpine rat model of epilepsy using [11C]-(R)-PK11195 PET and MRI</article-title><source>J. Cereb. Blood Flow Metab.</source><volume>37</volume><year>2017</year><fpage>1251</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">27381824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X16653615</pub-id><pub-id pub-id-type="pmcid">PMC5414902</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name name-style="western"><surname>Pugliese</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gaemperli</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kinderlerer</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Lamare</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shalhoub</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Rimoldi</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Camici</surname><given-names>P.G.</given-names></name></person-group><article-title>Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography</article-title><source>J. Am. Coll. Cardiol.</source><volume>56</volume><year>2010</year><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">20705222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2010.02.063</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name name-style="western"><surname>Wala</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>X.</given-names></name></person-group><article-title>Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender</article-title><source>Pharmacol. Res.</source><volume>41</volume><year>2000</year><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">10704271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/phrs.1999.0617</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name name-style="western"><surname>Abanades</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Der Aart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barletta</surname><given-names>J.A.R.</given-names></name><name name-style="western"><surname>Marzano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Searle</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Salinas</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Reiley</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Pampols-Maso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zamuner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Rabiner</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Laruelle</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>R.N.</given-names></name></person-group><article-title>Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy</article-title><source>J. Cereb. Blood Flow Metab.</source><volume>31</volume><year>2011</year><fpage>944</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">20940733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2010.175</pub-id><pub-id pub-id-type="pmcid">PMC3063628</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.S.</given-names></name></person-group><article-title>Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers</article-title><source>Clin. Pharmacol. Ther.</source><volume>81</volume><year>2007</year><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">17259948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100049</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>R.</given-names></name></person-group><article-title>In vivo site-directed radiotracers: a mini-review</article-title><source>Nucl. Med. Biol.</source><volume>35</volume><year>2008</year><fpage>805</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">19026942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nucmedbio.2008.10.002</pub-id></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name name-style="western"><surname>Fani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>C.</given-names></name><name name-style="western"><surname>Raynal</surname><given-names>I.</given-names></name><name name-style="western"><surname>Port</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maecke</surname><given-names>H.R.</given-names></name></person-group><article-title>Development of new folate-based PET radiotracers: preclinical evaluation of68Ga-DOTA-folate conjugates</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><volume>38</volume><year>2011</year><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">20799032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-010-1597-8</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name name-style="western"><surname>Mackowiak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Heyward</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Swaan</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Molecular basis of metabolism-mediated conversion of PK11195 from an antagonist to an agonist of the constitutive androstane receptor s</article-title><source>Mol. Pharmacol. Mol Pharmacol.</source><volume>92</volume><year>2017</year><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">28442602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.117.108621</pub-id><pub-id pub-id-type="pmcid">PMC5452073</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name name-style="western"><surname>Eberl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katsifis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peyronneau</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Loc'h</surname><given-names>C.</given-names></name><name name-style="western"><surname>Greguric</surname><given-names>I.</given-names></name><name name-style="western"><surname>Verschuer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mattner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fulham</surname><given-names>M.J.</given-names></name></person-group><article-title>Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [18F]PBR102 and [18F]PBR111</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><volume>44</volume><year>2017</year><fpage>296</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">27699720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-016-3517-z</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name name-style="western"><surname>Hargreaves</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Rabiner</surname><given-names>E.A.</given-names></name></person-group><article-title>Translational PET imaging research</article-title><source>Neurobiol. Dis.</source><volume>61</volume><year>2014</year><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">24055214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2013.08.017</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0085"><title>Acknowledgements</title><p id="p0145">We would like to thank all the members of preclinical PET group at the University of Edinburgh for their assistance during this study.</p></sec><sec id="s0090"><title>Funding</title><p id="p0150">The <funding-source id="gts0005">British Heart Foundation</funding-source> supported the purchase of equipment [BHF RE/13/3/20183 and RG/16/10/32375] and consumables [BHF PG/17/83/33370] used in this work. AS, TW and AT are supported by the <funding-source id="gts0010">British Heart Foundation</funding-source> [BHF RE/13/3/20183 and RG/16/10/32375]. CA and CL are funded by <funding-source id="gts0015">Edinburgh Preclinical Imaging</funding-source> and <funding-source id="gts0020">Edinburgh Imaging Facilities</funding-source>, respectively.</p></sec><sec id="s0095"><title>Declaration of interest</title><p id="p0155">None.</p></sec></ack></back></article></pmc-articleset>